In this information-packed webinar, neurologist Dr Lars Wojtecki talks about scientific background and clinical data of Transcranial Pulse Stimulation (TPS) in patients with Alzheimer’s Dementia as well as practical experience with handling and clinical effects.

Alzheimer's patients now also have access to Transcranial Pulse Stimulation (TPS) in Munich – one of the leading medical cities in Germany. In July 2021, a NEUROLITH® system was installed in the private practice Schleicher & Brückl. It is the first NEUROLITH® in the capital of Bavaria, the largest German state.

Transcranial Pulse Stimulation (TPS) with the NEUROLITH® system for the treatment of Alzheimer's patients is increasingly gaining momentum: In early June 2021, three more devices were installed in renowned neurological specialist clinics in Germany, Austria and Turkey.

The established and US-market leading MODULITH SLX-F2 extracorporeal shock wave lithotripter from STORZ MEDICAL has recently received the FDA 510 (k) clearance for new indications. With this clearance, an absolutely unique selling point for STORZ MEDICAL is that children over the age of three years suffering of stone disease can now be treated non-invasively^{(*1,2, 3)}. The MODULITH SLX-F2 is the first and the only lithotripter available for lithotripsy in children in the USA.

In early May 2021, two more NEUROLITH® systems were installed in Germany. Both the renowned Klinikum Wahrendorff in Sehnde near Hanover and the private practice of Prof. Dr Musa Citak in Hamburg are expanding their range of therapies with Transcranial Pulse Stimulation (TPS).